Enhanced umbilical cord adherent stem cell - CHA Biotech
Alternative Names: CordSTEM-ARDS; CordSTEM-AS; CordSTEM-CD; CordSTEM-COVID; CordSTEM-DD; Cordstem-ST; CordSTEM®; Human umbilical cord derived mesenchymal stem cell therapy - CHA BiotechLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator CHA Bio & Diostech
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Intervertebral disc degeneration; Stroke
- Phase I Primary ovarian insufficiency
- Preclinical Female genital diseases; SARS-CoV-2 acute respiratory disease
- No development reported Cartilage disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cartilage-disorders in South Korea (Parenteral)
- 29 Aug 2024 Phase-I clinical trials in Primary ovarian insufficiency (In adults) in South Korea (Parenteral) (NCT06578039)
- 17 Apr 2023 CHABiotech completes a Phase-I/II clinical trials in Intervertebral disc degeneration in South Korea (Parenteral) (NCT04530071)